1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Guhan Pharmaceutical Group Co., Ltd.

Guhan Pharmaceutical Group Co., Ltd.

000590.SZ
Guhan Pharmaceutical Group Co., Ltd.CN flagShenzhen Stock Exchange
8.12
CNY
+0.06
- -
1.94BMarket Cap
Guhan Pharmaceutical Group Co., Ltd.
000590.SZ
(Shenzhen Stock Exchange)

Recent

price

8.12

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.4
1.54
1.63
1.15
0.91
1.32
1.42
1.48
0.78
1.32
1.15
1.26
1.46
1.69
1.43
1.41
1.42
Revenue per Share
0.21
0.32
0.62
-0.74
-0.38
0.1
0.25
0.08
-0.16
0.18
0.09
0.15
0.08
0.11
-0.52
-0.21
-0.5
Basic EPS, GAAP
0.27
0.04
0.02
-0.05
-0.62
-0.41
-0.22
-0.48
-0.09
-0.03
0.07
- -
0.15
-0.21
-0.06
-0.08
-0.22
Free Cash Flow per Basic Share
0.02
0.02
0.09
0.2
0.02
0.01
- -
- -
0.01
0.01
- -
- -
- -
0.02
0.01
0.01
0.01
Dividend per Share
0.63
0.83
1.25
0.32
-0.07
0.03
0.28
0.42
0.25
0.43
0.52
0.67
0.75
0.85
0.33
0.12
0.26
Book Value per Share
0.64
1.02
1.55
0.55
0.13
0.07
0.38
1.79
1.85
2.04
2.12
2.29
1.7
1.94
1.91
1.78
1.85
Tangible Book Value per Share
223
223
223
223
223
223
223
233
240
240
239
239
240
240
239
239
239
Basic Weighted Avg Shares
312
344
363
256
203
295
317
344
186
315
275
301
351
405
343
338
339
Sales/Revenue/Turnover
21.04
26.5
12.92
-23.98
-29.36
12.1
7.81
4.82
-19.25
8.81
8.14
11.34
4.62
5.06
-5.71
-5.56
-7.36
Operating Margin (%)
14
15
17
17
13
14
15
14
16
14
14
19
24
28
29
32
- -
Depreciation Expense
47
72
138
-164
-86
22
55
19
-38
42
23
35
18
25
-125
-51
-119
Net Income, GAAP
15.58
17.96
25.31
- -
- -
27.53
24.36
55.12
- -
20.59
17.8
15.29
17.09
16.14
- -
- -
540.04
Effective Tax Rate (%)
15.13
21
37.86
-64.24
-42.23
7.59
17.38
5.58
-20.55
13.47
8.26
11.78
5.17
6.24
-36.56
-14.96
-35.18
Profit Margin (%)
-52
-9
175
36
-63
-26
30
358
346
338
348
367
258
291
264
178
261
Working Capital
- -
- -
- -
- -
- -
- -
- -
20
20
- -
9
6
95
83
84
51
97
LT Debt
279
361
479
270
184
206
264
583
580
622
645
682
702
728
601
549
584
Total Equity
18.37
22.1
8.81
- -
- -
15.6
8.78
1.9
- -
4.12
3.31
4.9
1.92
2.2
- -
- -
- -
Return on Invested Capital (%)
25.8
33.37
52.93
- -
- -
37.89
57.91
21.93
- -
43.76
18.84
23.12
7.82
9.47
- -
- -
145.4
Return on Capital (%)
40
44.03
59.05
-93.76
- -
- -
157.48
23.88
-48.42
52.41
20.01
24.84
10.69
13.21
-88.97
-95.27
-98.77
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
15
44
38
LT Borrowings
82
85
95
LT Finance Leases
1
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
239
239
239
Market Capitalization
1,702
2,037
2,562

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
500
514
495
Cash, Cash Equivalents & STI
177
145
217
Accounts Receivable, Net
8
7
4
Inventories
125
133
129
Total Current Liabilities
236
255
233
Payables & Accruals
- -
- -
- -
ST Debt
15
44
38
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.6%
-2.72%
-8.61%
Free Cash Flow
-618.81%
-1,150.56%
34.9%
Net Income, GAAP
-108.56%
-122.05%
-59.74%
Sales/Revenue/Turnover
5.14%
4.91%
-1.61%
Total Cash Common Dividend
140.76%
300.61%
-3.25%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
77
70
70
127
343
2025
65
77
113
- -
338
2026
72
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
- -
- -
- -
-0.52
2025
-0.07
- -
- -
- -
-0.21
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
Tycoon Group Holdings Limited (3390.HK)
Jianzhijia Pharmaceutical Chain Group Co., Ltd. (605266.SS)
MatsukiyoCocokara & Co. (3088.T)
Decipher Labs Ltd. (DECIPHER.BO)
Qol Holdings Co., Ltd. (3034.T)
Inhibikase Therapeutics, Inc. (IKT)
Business
Tus-Pharmaceutical Group Co., Ltd. operates primarily in the pharmaceutical sector, engaging in the development, production, and distribution of diverse medicinal and health products. The company offers an extensive portfolio, encompassing traditional Chinese medicines, Western pharmaceutical preparations, and health foods. Its product lines include nutritional supplements, remedies for cardiovascular and cerebrovascular conditions, children's nutrition, and treatments for colds and detoxification, alongside various injections. Recognized as a national high-tech enterprise, it stands as a significant entity within the proprietary Chinese medicine industry and is considered a leading integrated pharmaceutical company in Hunan, blending Chinese medicine, Western medicine, and biochemical products. The firm was established in 1956 and maintains its operational headquarters in Hengyang, China, having previously been known as Tus-Guhan Group Corp., Ltd.. Recent strategic moves include changes in ownership structure and various acquisitions and funding initiatives.